Toronto - GreenBank Capital Inc. (CSE: GBC and OTCMKTS: GRNBF and FRA: 2TL) ('GreenBank' or 'the Company') is very pleased to announce that following its previously announced commercial agreement to acquire a shareholding in, and provide merchant banking services to, Pharmakure, Pharmakure has successfully raised GBP4m (C$7m).

Some of the proceeds of the fundraising were used to acquire the Business and Assets of CynapseDx Ltd ('CDX') whose breakthrough biomarker technology is expected to dramatically enhance and complement PharmaKure's technology for the treatment of patients suffering Alzheimer's Disease and Related Dementias (ADRD). Richard Beresford, director of GreenBank Capital and Elisa Kahn of W Global Capital Limited co-lead and managed the C$7m fundraise and London-based international law firm, McCarthy Denning (www.mcarthydenning.com) acted for Pharmakure on the acquisition.

CDX's patent-pending technology consists of a series of biomarker assays which can uniquely determine the presence of the misfolded proteins which are the hallmarks of Alzheimer's, together with an apheresis technology which can cleanse the blood of affected patients by removing these proteins. These technologies are highly synergistic with Pharmakure's patented treatment for Alzheimer's disease by deploying repurposed, previously-approved drugs. Pharmakure plans to use the unique biomarker tests from CDX to screen its clinical trial candidates for the disease-causing proteins and then to test their drug on those blood samples. If the outcome yields a reduction in these proteins, then Pharmakure will be able to proceed with trials using those patients with the advance knowledge that the drugs will likely achieve the targeted therapeutic outcome. Such a predictable therapeutic result combined with the fact that the existing proven safety profile of the drugs dramatically increases the prospects of receiving regulatory approval for Pharmakure's drug candidates.

Dr. Farid Khan, CEO of Pharmakure explains, 'We will enter human trials faster, because our combination of 'repurposed' drugs is currently approved for use, one as an anti-depressant and the other as an anti-psychotic. We also know they will cross the blood brain barrier and will therefore target the brain. This combination of CDX's technologies with our ground-breaking proprietary formulations will accelerate a promising treatment for these debilitating diseases'.

Pharmakure will now proceed with its plan to list on the Canadian Securities Exchange following a reverse merger into a Canadian reporting issuer.

Subject to successful listing on the CSE, an institutional investor has committed to provide funding of up to CA$26m (dependent on the volume of trading in Pharmakure's shares after listing) in order to finance Pharmakure's Alzheimer Phase II Clinical Trials and to progress Pharmakure's other pipeline drugs.

In the event that Pharmakure's Phase II Clinical Trials succeed it is expected that the value of Pharmakure would increase significantly. Completion of Phase II trials is a major inflection point, which often leads to significant out-licensing deals with large Pharmaceutical firms.

About Pharmakure

Pharmakure was founded in 2012 as a spin out from the University of Manchester's world-leading Manchester Institute of Biotechnology.

The biotech company is a specialist in drug repurposing with focus on diseases of the Central Nervous System ('CNS'), and has a three-pronged business model.

The first part is to run Phase II clinical trials leading to an out-licensing deal. The lead candidate, PK 051, is a reformulation of two approved drugs targeting toxic b-amyloid oligomers (aggregates), a characteristic hallmark of 'plaques' in the brains of patients. In vitro and cell studies have shown that the drugs synergistically act as protein dis-aggregators. Pre-clinical studies using the combined drugs in an Alzheimer's mice model demonstrated a reduction in plaques by 40%. Because these two drugs are already approved, the company plans to move directly to Phase IIa/b trials in 2021 with a target to negotiate an out-licensing deal upon completion.

Second, the proprietary SSV technology (Screen-Select-Validate) created by the company is the engine to search for and develop new therapies from approved drugs to build out the pipeline, patent them, and then take them into fast-track clinical trials.

The third element of the business model is wrapped around the use and commercialisation of proprietary blood-based biomarkers which can identify and screen patients for early diagnosis.

Dr Farid Khan has worked at pharmaceutical giant GlaxoSmithKline in drug discovery, and, after obtaining a PhD from Cambridge University (2004), he then worked as a post-doctoral scientist at The Babraham Institute in protein arrays. Thereafter, Dr. Khan became team leader at the Molecular Biotechnology Group at The Institute of Biotechnology at The University of Manchester. He subsequently founded a number of successful bio-medtech companies including, in 2010, one focusing on recombinant proteins (CRO-Protein Technologies Ltd) and, in 2013, a medication adherence venture -Elucid mHealth Ltd. In 2015, in recognition of his pioneering work in biotechnology, he was awarded the Fazlur Rahman Khan award for excellence in engineering/science/technology by Prime Minister David Cameron.

Pharmakure's Chairman, Dr Ian Smith, was awarded an MBE 'for services to Health Research' for building a global clinical trials business called Synexus which was sold in 2016 for GBP178m. Chief Business Officer Tony Travers previously led the commercial transformation of AstraZeneca Infection business. Under the commercial leadership of Mr Travers, AstraZeneca's infection business increased sales from US$350 million in 2003 with a single brand, to a multi-brand business with sales of US$1.9 billion in 2011 together with a healthy pipeline of promising new drug treatments.

About GreenBank

GreenBank is a next generation merchant banking business that has a flexible low-cost overhead structure designed to maximize profitability. Our management are based in Toronto, Dallas, New York and London and are used to working across borders remotely. Our model of remote working, dynamic space and flexible contracts -rather than expensive offices, full time employees and large fixed costs - establishes GreenBank as a global merchant bank for the future, both during and after COVID19.

GreenBank is listed on the Canadian Securities Exchange, the Frankfurt Boerse and on the OTC Markets in the USA. GreenBank invests in undervalued exponential growth companies focused on building consistent capital appreciation for its shareholders.

Contact:

Mark Wettreich

Tel: +1 (647) 693 9411

Email: Mark@GreenBankCapitalinc.com

(C) 2021 Electronic News Publishing, source ENP Newswire